Matthew Cortese

Medical Oncology and Hematology

Specializing In:

B-cell lymphomas Chronic lymphocytic leukemias (CLL/SLL, HCL) Clinical trial design

About Matthew Cortese


As a lymphoma specialist, I treat all forms of lymphoma, but have a primary clinical and research focus in CLL/SLL and B-cell Non-Hodgkin Lymphomas.  My research focus is to develop a better understanding of the mechanisms of treatment resistance for many lymphomas, as well as to investigate the molecular mechanisms by which low-grade lymphomas transform into more aggressive high-grade lymphomas (e.g. Richter Transformation), in an effort to optimize treatments and provide more detailed prognostic information. 

I am actively involved in clinical trial design and implementation (including novel cellular and targeted therapies), in ongoing efforts to provide better treatments and hope to our patients.  I was born and raised in Upstate New York, and am honored and privileged to be able to provide care as part of an outstanding team here at Roswell Park.


Roswell Park Comprehensive Cancer Center

  • Assistant Professor of Oncology
  • Department of Medicine, Lymphoma


Education and Training:

  • 2011-2016 - MD - State University of New York Upstate Medical University, Syracuse, NY
  • 2013-2016 - MPH with a focus on Health Policy and Program Development - Syracuse University and State University of New York Upstate Medical University, Syracuse, NY


  • 2016-2019 - Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH


  • 2019-2022 - Hematology/Oncology, Cleveland Clinic Foundation, Cleveland, OH

Board Certification:

  • Internal Medicine - American Board of Internal Medicine
  • Hematology and Medical Oncology (Board Eligible) - American Board of Medical Specialties

Professional Memberships:

  • American Society of Hematology (ASH)
  • American Society of Clinical Oncology (ASCO)
  • American Society for Transplantation and Cellular Therapy (ASTCT)
  • American Medical Association (AMA)


Cortese MJ, Wei W, Cerdena S, Watkins M, Olson M, Jodon G, Kaiser J, Haverkos B, Hughes ME, Grover NS, Snow A. A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma. Blood. 2020 Nov 5;136:32-4.

Sohail MA, Li H, Wei W, Cerdena S, Watkins M, Olson M, Jodon G, Kaiser J, Haverkos B, Hughes ME, Grover NS. Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma. Blood. 2020 Nov 5;136:24-5.

Cortese MJ, Wei W, Hill BT. Outcomes of Active Surveillance Versus Initial Treatment for Nodular Lymphocyte Predominant Hodgkin Lymphoma: A National Cancer Database (NCDB) Analysis of 2,480 Patients. Blood. 2020 Nov 5;136:29-30.

George LL, Deshpande SR, Cortese MJ, Kendall EK, Chattaraj A, Shah Z, Zhao J, Anwer F. Emerging targets and cellular therapy for relapsed refractory multiple myeloma: a systematic review. Clinical Lymphoma Myeloma and Leukemia. 2021 Nov 1;21(11):741-51.

Radakovich N, Cortese M, Nazha A. Acute myeloid leukemia and artificial intelligence, algorithms and new scores. Best Practice & Research Clinical Haematology. 2020 Sep 1;33(3):101192.

Haarer B, Mi-Mi L, Cho J, Cortese M, Viggiano S, Burke D, Amberg D. Actin dosage lethality screening in yeast mediated by selective ploidy ablation reveals links to urmylation/wobble codon recognition and chromosome stability. G3: Genes, Genomes, Genetics. 2013 Mar 1;3(3):553-61.